Filing Flows

Filing Flows › 8-K events › Recursion Pharmaceuticals

Recursion Pharmaceuticals: results of operations

Form 8-K filed Nov 2, 2026 · items 2.02, 5.02, 7.01

FDA decisionsRecursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred

What the filing says

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair • New Phase 2 REC-4881 data presented at CGA-IGC in an expanded adult population aged 18 years and older

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Item 5.02: −0.1% next session across 39,174. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Recursion Pharmaceuticals at a glance

Latest quarterQ3 2026
Revenue$18.6M
Revenue Y/Y+258%
Operating margin-663.9%
IndustryBiological Products, (No Diagnostic Substances)

Recursion Pharmaceuticals, Q3 2026: revenue $18.6M (+258% year over year), operating margin -663.9%. The chart follows the revenue to costs, profit and cash.

Recursion Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.